The 3rd Glioblastoma Drug Development Summit, page-13

"In the initial abstract presentation of patients treated at the 1st dose level, a disease control rate of 75% was shown as 3 out of the 4 patients treated achieved a best response of stable disease assessed by RANO criteria. Additional details provided within the final presentation demonstrated that the disease control observed was durable for approximately 5-8 weeks."

"The CLTX CAR T phase 1 clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022. The design is a single arm, open label trial in patients with MMP2+ recurrent or progressive glioblastoma. The primary endpoints of the trial are to assess the safety of CLTX CAR T cells, determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan. Secondary
endpoints include bioactivity and efficacy measures."

Don't hold your breath.